TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05257109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with no alteration to water concentration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.
Study: NCT05659771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food properties manipulation to alter eating behavior and food and energy intake
Description: Food properties of commercially available food products

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food properties manipulation to alter eating behavior and food and energy intake
Description: Food properties of commercially available food products
Study: NCT05257109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 5% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 10% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 4
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 4
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 4
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Concentration 4
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with 20% total water concentration of e-liquid.
Study: NCT05168943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nylon (Polyamide) Epidural Catheter
Description: Nylon (Polyamide) Epidural Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyurethane Epidural Catheter
Description: Polyurethane Epidural Catheter
Study: NCT05726110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homoharringtonine
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclacinomycin
Description: Given per standard of care
Study: NCT05621317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-108
Description: PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-108
Description: PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-108
Description: PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comprises the formulation vehicle without peptides

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo comprises the formulation vehicle without peptides
Study: NCT04812548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Sabatolimab was administered at a low dose (Safety run-in (Part 1) cohort 1) or a high dose (Safety run-in (Part 1) cohort 2) via i.v. infusion over 30 minutes on Day 8 of every treatment cycle. Cycle = 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: A standard dose of azacitidine was given subcutaneously or intravenously every day for seven consecutive days on days 1-7 of a confirmed treatment cycle. In keeping with standard clinical practice, the alternative schedules for five consecutive days on days 1-5, followed by a two day break, then two consecutive days on days 8-9 was permitted (alternative schedule).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Venetoclax film-coated tablets was administered at a dose of 400 mg orally or corresponding reduced dose for concomitant use with P-gp inhibitors or moderate or strong CYP3A4 inhibitors, once a day, from C1D1 to C1D14 during the treatment cycle. No ramp-up for venetoclax was necessary.
Study: NCT05570214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality device will be viewing calming narrated scenarios with relaxing music of walking through a forest, along a beach, through a Chinese garden, a winter landscape or taking off in a spaceship or snorkeling through a reef
Study: NCT06491264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation
Description: We will administer active transcranial electrical stimulation in one of the 4 active stimulation conditions and 1 sham stimulation condition.
Study: NCT05299359

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-019
Description: TAK-019 intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-019
Description: TAK-019 intramuscular injection
Study: NCT04780776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVB treatment
Description: 5 weeks of UVB titration to determine individual's UVB sensitivity followed by 16 weeks of UVB exposure intervention

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: 5+16 weeks of visible light exposure
Study: NCT06504290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo （in healthy adult subjects）
Description: VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days.
Study: NCT06504290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 （in healthy adult subjects）
Description: VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119(in adult patients with schizophrenia)
Description: VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV119 Placebo （in adult patients with schizophrenia）
Description: VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
Study: NCT05774080

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT05319652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain self-management program
Description: Each week for eight weeks, participants are invited to complete self-directed lessons on particular themes. The program covers goal setting, stress management through relaxation, breathing and mindfulness, pacing, physical activity, thoughts and emotions, sleep, nutrition, flare-up management, and planning. Through pain education, positive testimonials from individuals with CNCP applying the suggested strategies, reflective activities, goal setting and monitoring, and the gradual development of a personal plan, the program supports self-efficacy building to manage CNCP.
Study: NCT04492488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study: NCT06439134

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Ultrasound, Respiratory Function Test
Description: Volunteers underwent pulmonary ultrasound and respiratory function test

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Ultrasound, Respiratory Function Test
Description: Volunteers underwent pulmonary ultrasound and respiratory function test
Study: NCT04461912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye Scan Ultrasound System (ESUS)
Description: • For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Eye Scan Ultrasound System (ESUS)
Description: • For the ultrasonic signals acquisitions, an ophthalmic probe working in A-mode scan, must be coupled to the cornea. To reduce the discomfort generated by coupling the probe, topical anaesthesia (oxybuprocaine hydrochloride) will be applied before starting acquisitions. However, if the participant has some known contraindication to this anaesthetic, in replacement, a disposable neutral contact lens will be used as coupling medium between the probe and the cornea.~The acquisitions are initiated through a starting button in the system's user interface, and the probe must be kept by few seconds for automatic signals records. During this period, signals are visualized in the user interface. Finally the probe is uncoupled, and the acquired signals are saved.
Study: NCT05872113

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hs-hWE cream
Description: The cream was applied to the faces of subjects, the left facial area was put on the 0.5% Hs-WE cream.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The cream was applied to the faces of subjects, the right facial area was put on the placebo cream.
Study: NCT05311111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal radial artery approach
Description: Procedure: Use of radial artery for access for a coronary angiography or intervention After preparation and local anesthesia, the operator will puncture the distal radial artery in the dorsum of the hand or the anatomical snuff-box. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional radial artery approach
Description: Procedure: conventional radial access for a percutaneous coronary intervention After preparation and local anesthesia, the operator will puncture the proximal radial artery at the conventional site in distal forearm. Then a sheath will be placed. A cocktail combining Risordan®, Loxen® and unfractionated heparin will be injected through the sheath. a wire will be introduced. At the end of the procedure, the sheath will be removed immediately and hemostasis by compression will be carried out with an elastic band for 12 hours. The choice of limb side, sheath, catheters will be chosen according to the operator's discretion.
Study: NCT04892082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Moment
Description: The Mindful Moment program is a web-based self-guided cognitive-behavioral intervention to reduce parenting stress, targeting postpartum mothers. It consists of 6 weekly modules, each module targeting a specific thematic content, and providing mothers with both information and specific therapeutic strategies (with a strong focus on the third wave of cognitive-behavioral techniques) to address each thematic content. Modules are sequential.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting-List Control (WLC)
Description: The control group only receive the intervention at the end of the intervention group.
Study: NCT05146609

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV. HR-HOSPITAL
Description: Screening HCV in high risk population by themselves or at referral hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV. HR-DDP
Description: Screening HCV in high risk population by themselves or at drug dependence center.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV. GP-HOSPITAL
Description: Screening HCV in general population by themselves or at referral hospital.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening HCV. GP-PCC
Description: Screening HCV in general population by themselves or at primary care center.
Study: NCT05367570

Intervention type: BEHAVIORAL
Intervention: Cross-sectional observational study
Description: The first work package of this project is an explanatory cross-sectional study with no intervention.
Study: NCT04869475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: This is a single-arm study with all patients receiving arsenci trioxide.
Study: NCT06249438

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD20/BCMA-directed CAR-T cells
Description: Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously
Study: NCT04998396

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV9 BBP-812
Description: Sterile solution for injection for 1-time use via volumetric infusion pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV9 BBP-812
Description: Sterile solution for injection for 1-time use via volumetric infusion pump

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV9 BBP-812
Description: Sterile solution for injection for 1-time use via volumetric infusion pump
Study: NCT05745441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Dinner
Description: Dinner before DLMO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Dinner
Description: Dinner before DLMO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner after DLMO

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner after DLMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Dinner tracer
Description: Stable isotope of oral \[2H31\] palmitate to measure fat oxidation, given with dinner before DLMO
Study: NCT05460338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: native form of Vitamin D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: native form of Vitamin D.
Study: NCT05397769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab Plus Chemoradiotherapy
Description: Envafolimab was administrated with 300mg each time, every three weeks for a total of 22 cycles since the first day of induction chemotherapy.
Study: NCT05940701

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Curasept Biosmalto Mousse and toothpaste
Description: at each visit a Curasept Biosmalto Mousse will be applied on the facial surface of the maxillary and mandibular anterior teeth using a tray.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colgate toothpaste
Description: The control group will receive a fluoridated toothpaste (Colgate toothpaste)
Study: NCT05711121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal epidural steroid injection
Description: Fluoroscopy-guided transforaminal epidural injection for radicular pain resulting from a disc herniation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural steroid injection
Description: Fluoroscopy-guided caudal epidural injection for radicular pain resulting from a disc herniation.
Study: NCT05864326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm group
Description: The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of Heated saline water (NaCl 0.9%) at 40°C - according to the mechanic resistance with a graduated syringe.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature group
Description: The operator will introduce a 14Fr or 18Fr Balloon catheter through the cervical canal, up above the internal orifice using a long Pean clamp and inflate the internal balloon with 30 to 80ml of unheated saline water (NaCl 0.9%) - according to the mechanic resistance with a graduated syringe.
Study: NCT06532084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg bid for 168 days starting in the time fram between engraftment with neutrophils \> 1.0 x 10\^9/L, white blood cells\> 1.5 x 10\^9/L, platelets\> 1.5 x 10\^9/L and day+100 after allogeneic hematopoietic cell trnaplantation
Study: NCT05957965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wii fit
Description: Nintendo Wii console (Nintendo Co., Ltd, Kyoto, Japan) is the main power unit of Nintendo Wii Fit. Its software includes an interactive video games that is played with a handheld, wireless remote that senses motion and requires the participant to mimic the action of their on - screen character. These games are played using a special Wii balance board in order to perform activities like yoga, balance and aerobics. The Wii remote is the primary controller for Nintendo's Wii console. The motion sensing capability is the main feature of it. It allows the user to interact with and manipulate items on screen via pointing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening, proprioceptive exercises.
Description: -Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening, proprioceptive exercises.
Description: -Strengthening exercise: Ankle Dorsiflexion and Plantar Flexion \& inversion and eversion Strengthening with Exercise Bands~-Proprioceptive exercise using wobble board
Study: NCT06579950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cool roof
Description: Cool roofs are a sunlight reflecting roof coating that can reduce indoor temperature. Cool roofs have high solar reflectance (reflecting the ultraviolet and visible wavelengths of sunlight, reducing heat transfer to the surface of a roof) and high thermal emittance (radiating absorbed solar energy).
Study: NCT05173896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: Daily dose of oral over-encapsulated tadalafil tablets (20 mg) for three months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of oral over-encapsulated placebo tablets for three months.